RXRX (Recursion Pharmaceuticals) Marketable Securities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.05
GF Value $4.07
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Marketable Securities?

Recursion Pharmaceuticals RXRX +1.02% 77 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.07 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Recursion Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Recursion Pharmaceuticals  (NAS:RXRX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Recursion Pharmaceuticals Marketable Securities Related Terms

Recursion Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Marketable Securities Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 231.45 0.00 0.00 0.00 0.00

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Recursion Pharmaceuticals (RXRX) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Marketable Securities too high?
Recursion Pharmaceuticals' current Marketable Securities is $0.00 Mil. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Marketable Securities compare to INVA and TSHA?
Recursion Pharmaceuticals' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.07, compared to a current price of $3.05 — trading 25.1% below its estimated fair value. The current Marketable Securities is $0.00 Mil. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.05 is trading 25.1% below its estimated GF Value™ of $4.07. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for RXRX:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $4.07 vs. price of $3.05 (25.1% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.05
Price
$4.07
GF Value